Kymera Therapeutics (KYMR) Enterprise Value (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Enterprise Value of -$650.9 million for Q1 2026, down 40.54% year-over-year from -$1.1 billion in Q1 2025, and up 23.26% quarter-over-quarter from -$848.3 million in Q4 2025.
Kymera Therapeutics (KYMR) Enterprise Value (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Enterprise Value for 8 consecutive years, with -$650.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 40.54% year-over-year to -$650.9 million; the TTM figure through Mar 2026 stood at -$650.9 million (down 40.54% YoY), while the FY2025 annual figure was -$848.3 million, down 73.56% from the prior year.
- Enterprise Value grew to -$650.9 million in Q1 2026 per KYMR's latest filing, from -$848.3 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$33.7 million in Q1 2022 and bottomed at -$848.3 million in Q4 2025.
- Historically, Enterprise Value has averaged -$452.9 million across 5 years, with a median of -$481.9 million in 2022.
- Annual changes were most pronounced in 2022 — Enterprise Value jumped 89.89% — and 2023, when it plunged 1076.52%.
- Kymera Therapeutics' Enterprise Value stood at -$407.2 million in 2022, then advanced by 7.93% to -$374.9 million in 2023, then slumped by 30.37% to -$488.7 million in 2024, then plunged by 73.56% to -$848.3 million in 2025, then increased by 23.26% to -$650.9 million in 2026.
- Business Quant data shows KYMR's Enterprise Value at -$650.9 million in Q1 2026, -$848.3 million in Q4 2025, and -$505.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - | -690.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -690.99 Mn |
| Mar 31, 2026 | -650.93 Mn |
| Dec 31, 2025 | -848.28 Mn |
| Sep 30, 2025 | -505.68 Mn |
| Jun 30, 2025 | -665.45 Mn |
| Mar 31, 2025 | -463.15 Mn |
| Dec 31, 2024 | -488.74 Mn |
| Sep 30, 2024 | -549.97 Mn |
| Jun 30, 2024 | -509.95 Mn |
| Mar 31, 2024 | -520.54 Mn |
| Dec 31, 2023 | -374.88 Mn |
| Sep 30, 2023 | -357.83 Mn |
| Jun 30, 2023 | -367.57 Mn |
| Mar 31, 2023 | -396.88 Mn |
| Dec 31, 2022 | -407.17 Mn |
| Sep 30, 2022 | -481.91 Mn |
| Jun 30, 2022 | -76.91 Mn |
| Mar 31, 2022 | -33.73 Mn |
| Dec 31, 2021 | -442.42 Mn |
| Sep 30, 2021 | -536.39 Mn |